.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The PRODIGE 23 trial tested a total-neoadjuvant strategy that introduced modified FOLFIRINOX before standard chemoradiotherapy, total mesorectal excision and postoperative chemotherapy in patients with locally advanced rectal cancer. The central question was whether delivering more systemic treatment before surgery could improve long-term disease control. The trial showed improved disease-free and metastasis-free outcomes with the intensified neoadjuvant strategy compared with standard treatment. These findings are particularly relevant because distant metastatic relapse remains a major challenge in rectal cancer even after technically successful surgery. For clinicians, the study reinforces the concept that systemic risk should influence treatment sequencing. Giving effective systemic therapy earlier may improve completion of treatment and reduce the chance that chemotherapy is delayed or omitted after a major pelvic operation. At the same time, the approach requires careful patient selection because treatment intensity, toxicity and functional status must be weighed against potential oncological benefit. PRODIGE 23 helped establish total-neoadjuvant therapy as a major contemporary strategy for locally advanced rectal cancer. Its practical impact is the shift toward an integrated treatment plan in which systemic therapy, radiation, imaging and surgery are deliberately sequenced around the patient's risk rather than treated as disconnected steps.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The PRODIGE 23 trial tested a total-neoadjuvant strategy that introduced modified FOLFIRINOX before standard chemoradiotherapy, total mesorectal excision and postoperative chemotherapy in patients with locally advanced rectal cancer. The central question was whether delivering more systemic treatment before surgery could improve long-term disease control. The trial showed improved disease-free and metastasis-free outcomes with the intensified neoadjuvant strategy compared with standard treatment. These findings are particularly relevant because distant metastatic relapse remains a major challenge in rectal cancer even after technically successful surgery. For clinicians, the study reinforces the concept that systemic risk should influence treatment sequencing. Giving effective systemic therapy earlier may improve completion of treatment and reduce the chance that chemotherapy is delayed or omitted after a major pelvic operation. At the same time, the approach requires careful patient selection because treatment intensity, toxicity and functional status must be weighed against potential oncological benefit. PRODIGE 23 helped establish total-neoadjuvant therapy as a major contemporary strategy for locally advanced rectal cancer. Its practical impact is the shift toward an integrated treatment plan in which systemic therapy, radiation, imaging and surgery are deliberately sequenced around the patient's risk rather than treated as disconnected steps.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
4 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
